PMID- 24743200
OWN - NLM
STAT- MEDLINE
DCOM- 20140520
LR  - 20161125
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 41
IP  - 2
DP  - 2014 Feb
TI  - [Efficacy and safety of eribulin for metastatic breast cancer patients].
PG  - 215-9
AB  - In the EMBRACE trial, eribulin was reported to significantly increase overall 
      survival compared to treatment of the physician 's choice when given to patients 
      with recurrent or metastatic breast cancer who had received prior treatment, 
      including an anthracycline and a taxane. In April 2011, eribulin was approved in 
      Japan for the treatment of inoperable or recurrent breast cancer. In this 
      article, we report on the efficacy and safety of eribulin in cases we 
      encountered. Twenty patients with advanced and recurrent breast cancer were 
      administered eribulin in our hospital during the period from August 2011 to 
      December 2012. The median age was 62 years(range, 42-76 years); 16 patients had 
      the estrogen receptor(ER)(+)/human epidermal growth factor receptor 
      2(HER2)(-)subtype, whereas 4 patients had the triple-negative subtype. Following 
      recurrence, the median number of chemotherapy regimens was 3(range, 0-5). 
      Regarding the antitumor effects of eribulin, no cases showed complete 
      response(CR), 5 cases showed partial response(PR), and 10 cases showed stable 
      disease(SD); therefore, the response rate(CR+PR)was 25% and the clinical benefit 
      rate(CR+PR+B6-month SD)was 35%. Median progression free survival was 146 days, 
      and median overall survival was 482 days. In terms of adverse events(AEs), 
      observed cases of hematotoxicity were of neutropenia(75%), leucopenia(75%), and 
      anemia(80%). Cases of Grade 3 hematotoxicity or higher were of neutropenia(40%), 
      leucopenia(20%), and febrile neutropenia(1 case, 5%). The observed 
      non-hematotoxic AEs were peripheral neuropathy(30%)and general malaise(35%), 
      although none were of Grade 3 or higher. The therapeutic efficacy of eribulin in 
      the present study was relatively better than that in previous reports(EMBRACE 
      trial, Japan Domestic 221 trial). The frequency of Grade 3 or higher AEs was low, 
      and the drug was well tolerated. We believe that eribulin is a novel drug that 
      provides therapeutic efficacy while maintaining quality of life(QOL).
FAU - Okishiro, Masatsugu
AU  - Okishiro M
AD  - Dept. of Surgery, Kansai Rosai Hospital.
FAU - Egawa, Chiyomi
AU  - Egawa C
FAU - Kusama, Hiroki
AU  - Kusama H
FAU - Matsushita, Katsunori
AU  - Matsushita K
FAU - Hashimoto, Naoyoshi
AU  - Hashimoto N
FAU - Kawashima, Hiroshi
AU  - Kawashima H
FAU - Mukai, Yosuke
AU  - Mukai Y
FAU - Hamanaka, Michiko
AU  - Hamanaka M
FAU - Takeno, Atsushi
AU  - Takeno A
FAU - Sakisaka, Hideki
AU  - Sakisaka H
FAU - Nakahira, Shin
AU  - Nakahira S
FAU - Taniguchi, Hirokazu
AU  - Taniguchi H
FAU - Suzuki, Rei
AU  - Suzuki R
FAU - Takeda, Yutaka
AU  - Takeda Y
FAU - Kato, Takeshi
AU  - Kato T
FAU - Tamura, Shigeyuki
AU  - Tamura S
FAU - Takatsuka, Yuichi
AU  - Takatsuka Y
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Furans)
RN  - 0 (Ketones)
RN  - LR24G6354G (eribulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Furans/adverse effects/*therapeutic use
MH  - Humans
MH  - Ketones/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Recurrence
MH  - Treatment Outcome
EDAT- 2014/04/20 06:00
MHDA- 2014/05/21 06:00
CRDT- 2014/04/19 06:00
PHST- 2014/04/19 06:00 [entrez]
PHST- 2014/04/20 06:00 [pubmed]
PHST- 2014/05/21 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2014 Feb;41(2):215-9.